Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

    Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017. Nutlin-3a purchased from Selleck.

    Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NXHUUo1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;DTWM2OD1yLk[xNlM4KM7:TR?= M1r3S3NCVkeHUh?=
H4 NIOyUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;sTWM2OD1yLk[2Nlgh|ryP NGjJO2NUSU6JRWK=
PA-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XrO2lEPTB;MD64O|A6PiEQvF2= MWDTRW5ITVJ?
NKM-1 NX\UPI5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;FfIlKSzVyPUGuNFQ6OzFizszN MVXTRW5ITVJ?
NEC8 NHfIWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXhTWM2OD1zLkKxOVczKM7:TR?= NFX3NFFUSU6JRWK=
EoL-1-cell NYfxcllqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLVflZKSzVyPUGuNlY4ODFizszN MmGyV2FPT0WU
K5 NVLXfFJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH0TWM2OD1zLkSyNFczKM7:TR?= MmPIV2FPT0WU
QIMR-WIL NW\UT5FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[zOWlEPTB;MT62NFg2PCEQvF2= Ml\6V2FPT0WU
MOLT-16 M{W4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnBTWM2OD1zLke4OlA1KM7:TR?= MoTIV2FPT0WU
CHP-212 NG\HcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnoTWM2OD1zLkixN|Y6KM7:TR?= Ml\jV2FPT0WU
CTB-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX5SlVKSzVyPUKuNFIzPDZizszN MlrnV2FPT0WU
MOLT-4 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjQN45KSzVyPUKuN|I5PTNizszN MkjyV2FPT0WU
A101D NV\xRos{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUCzNWdXUUN3ME2yMlM2ODFizszN NY\neVM{W0GQR1XS
DOHH-2 NEHrWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D1XmlEPTB;Mj60NlI4QSEQvF2= MknnV2FPT0WU
ES4 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJwNEOxOVUh|ryP MoTTV2FPT0WU
SW780 M4X3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;w[Y9[UUN3ME2yMlUxQDh|IN88US=> NUn1eYd5W0GQR1XS
VA-ES-BJ NGLuXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV72NVRlUUN3ME2yMlU1OTFizszN MWfTRW5ITVJ?
RPMI-8866 M33scGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHMTWM2OD1{LkW2NlE1KM7:TR?= MnG5V2FPT0WU
ML-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHmTWM2OD1{LkW2OVc3KM7:TR?= MkTrV2FPT0WU
MSTO-211H MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJwNUe0OVEh|ryP MWXTRW5ITVJ?
JVM-3 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnSzTWM2OD1{LkW5N|I1KM7:TR?= MX7TRW5ITVJ?
A3-KAW MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:xTWM2OD1{Lk[xPFE5KM7:TR?= MYDTRW5ITVJ?
DK-MG NW\vWYRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXzO5R[UUN3ME2yMlYzPDdzIN88US=> MnzzV2FPT0WU
LNCaP-Clone-FGC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn2TWM2OD1{Lk[0N|E5KM7:TR?= Ml\OV2FPT0WU
HT-144 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XXXGlEPTB;Mj62OFU4PyEQvF2= M3;4[3NCVkeHUh?=
NB69 NH\CR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLZTWM2OD1{Lk[1N|M1KM7:TR?= MWrTRW5ITVJ?
A172 Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJwNke1PFgh|ryP MorCV2FPT0WU
RS4-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnNRW1KSzVyPUKuO|I1ODdizszN MWjTRW5ITVJ?
DU-4475 NIXrb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LLbWlEPTB;Mj63PVUxOiEQvF2= M4jXXHNCVkeHUh?=
SJSA-1 NXXPNG5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPVTWM2OD1{LkiyOVU3KM7:TR?= MoG5V2FPT0WU
BV-173 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn20TWM2OD1{Lki0OFM6KM7:TR?= NX\Eb5R{W0GQR1XS
U-2-OS Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHXTWM2OD1{LkmxNFch|ryP MkLjV2FPT0WU
CHP-134 NXHoSXZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwOUO4PFIh|ryP MWPTRW5ITVJ?
D-502MG MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnndZBSUUN3ME2yMlk4OTV2IN88US=> MlvkV2FPT0WU
KS-1 NWLFVoM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHnT2RKSzVyPUOuNFE3OjNizszN NFXxOHJUSU6JRWK=
A204 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTNwMEW1PFgh|ryP M2DqVXNCVkeHUh?=
KGN NUjNXW9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTvTlFKSzVyPUOuNFg1QTZizszN MVLTRW5ITVJ?
NCI-H292 MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fLNGlEPTB;Mz6xNlAzQCEQvF2= NV;2OYFLW0GQR1XS
CAKI-1 NFX0UHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTNwMUK2PVQh|ryP NX60OnlCW0GQR1XS
C2BBe1 MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MluzTWM2OD1|LkG3NFI3KM7:TR?= MUTTRW5ITVJ?
NB10 NECwR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfDTWM2OD1|LkKwPVY3KM7:TR?= MkLSV2FPT0WU
MHH-NB-11 M37pZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTNwMk[4Nlch|ryP M331SHNCVkeHUh?=
NCI-SNU-1 MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPJXlJKSzVyPUOuNlc5PDNizszN NUnB[lhvW0GQR1XS
HCT-116 NVe0dY9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfUTGRKSzVyPUOuN|A{OzVizszN NFXUW5ZUSU6JRWK=
G-401 NVvTTY1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nYbGlEPTB;Mz6zOlMzOiEQvF2= M4LORXNCVkeHUh?=
MN-60 MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEP6fXpKSzVyPUOuOFQxQTJizszN NEDaTnFUSU6JRWK=
SW982 NY\ac4o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfaW5pKSzVyPUOuOVA5PDhizszN MkHHV2FPT0WU
RKO M2GyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXKRmJKSzVyPUOuOVM6OzZizszN MmK0V2FPT0WU
D-283MED M2S4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTC[ld7UUN3ME2zMlU4QTh4IN88US=> NGnVblVUSU6JRWK=
LB996-RCC NHmwZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fGSmlEPTB;Mz62NlU2QCEQvF2= NIS5XYxUSU6JRWK=
A549 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjHXVA6UUN3ME2zMlY{PTV{IN88US=> NXW5N|c5W0GQR1XS
LB2241-RCC Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P1PWlEPTB;Mz62OVcxQCEQvF2= MlHNV2FPT0WU
SK-HEP-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTNwN{SyPVch|ryP MUfTRW5ITVJ?
G-402 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3D[W1VUUN3ME2zMlgxQDN{IN88US=> M2fXfnNCVkeHUh?=
GOTO NXPPOIQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPBTWM2OD1|Lki0N|M{KM7:TR?= NEj1PG5USU6JRWK=
LOXIMVI NInQeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvnVFhCUUN3ME2zMlg2Pjd3IN88US=> MXrTRW5ITVJ?
NH-12 NFn1R2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q0VGlEPTB;ND6wNVk2QSEQvF2= NFnxb41USU6JRWK=
CTV-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;jTWM2OD12LkC3PVc{KM7:TR?= M1PEc3NCVkeHUh?=
CP50-MEL-B NXy4VGMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTRwMkSzPVIh|ryP NXjvTVR4W0GQR1XS
RH-18 NVjUd2pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;j[GlEPTB;ND6yO|cxPiEQvF2= MW\TRW5ITVJ?
NB17 MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjh[I97UUN3ME20MlMyPzZ6IN88US=> NGjLcHlUSU6JRWK=
A375 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlOwTWM2OD12LkOzOVI1KM7:TR?= MUPTRW5ITVJ?
IST-MES1 NHPNepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC2TWM2OD12LkSxOFEyKM7:TR?= MWDTRW5ITVJ?
MZ2-MEL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTRwNUCxOVUh|ryP NF7MSoZUSU6JRWK=
CAL-54 MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\uTWM2OD12LkWzNFE6KM7:TR?= M4jYdXNCVkeHUh?=
NCI-H28 NFPIWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O2VmlEPTB;ND62NlcyPyEQvF2= MWnTRW5ITVJ?
D-247MG MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y4bGlEPTB;ND63OVA4OiEQvF2= NIDzbYlUSU6JRWK=
NCI-H460 NWfZSmpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T6emlEPTB;ND65NVEzPyEQvF2= NHTKNmRUSU6JRWK=
MCF7 M{D5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe3UHhKSzVyPUWuOFQzPDRizszN MW\TRW5ITVJ?
697 MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjrVYcxUUN3ME21MlQ1PTVizszN NInYU3lUSU6JRWK=
ONS-76 NUHacGNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HNbWlEPTB;NT61O|AxQSEQvF2= NVLsb3RoW0GQR1XS
C32 Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3xTVJKSzVyPUWuOlAxOjlizszN MWTTRW5ITVJ?
OS-RC-2 NUDFWoM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfnTWM2OD13LkezPFg4KM7:TR?= MkLzV2FPT0WU
MEL-HO M1jkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17yXGlEPTB;NT64OVY3PyEQvF2= MUXTRW5ITVJ?
LoVo NWfB[pluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XnXWlEPTB;Nj6wNVYzPCEQvF2= MkfJV2FPT0WU
AGS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XabGlEPTB;Nj6xOFgzQCEQvF2= Mni0V2FPT0WU
GI-ME-N NGTrUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;LR|VKSzVyPU[uNlI1OjFizszN NGHVe4FUSU6JRWK=
H-EMC-SS NULjdmh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnsRllLUUN3ME22MlM5PiEQvF2= M4rGTXNCVkeHUh?=
RVH-421 NFjmb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TCWGlEPTB;Nj60NlQzQCEQvF2= NUXhbVdPW0GQR1XS
SW954 Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf3bZkxUUN3ME22MlU2PTd{IN88US=> NEm1[I5USU6JRWK=
NB5 NFL3OW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLvTWM2OD14LkW2NVg{KM7:TR?= NFKz[pNUSU6JRWK=
NCI-H2122 NETqXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrmUmJVUUN3ME22MlU5Pzl|IN88US=> M1nKUXNCVkeHUh?=
AM-38 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTZwN{W2N|kh|ryP NFHQSllUSU6JRWK=
KNS-81-FD MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rhWWlEPTB;Nj63OlQ6PCEQvF2= Mnv3V2FPT0WU
LS-513 M{[zS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3KZm1wUUN3ME22Mlc6ODJ4IN88US=> M4DyPHNCVkeHUh?=
A427 M4HDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLBTWE4UUN3ME22Mlg4QDJ7IN88US=> NHXD[YlUSU6JRWK=
WM-115 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTZwOUOyN{DPxE1? NF;I[|lUSU6JRWK=
COLO-829 NXqzSplqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO2[WR6UUN3ME23MlI1OTh6IN88US=> NIi2ZXNUSU6JRWK=
NCI-H1650 MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jaNGlEPTB;Nz6zPVIzQCEQvF2= NFW5fnlUSU6JRWK=
NCI-H358 M1GxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rNN2lEPTB;Nz60OFg4QSEQvF2= NXPmUYxrW0GQR1XS
HT-1080 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPleIpKSzVyPUeuOFgzPTRizszN NFK2RZhUSU6JRWK=
HCC2218 NVHM[Iw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zidGlEPTB;Nz62Nlk4KM7:TR?= MV7TRW5ITVJ?
NCI-H661 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3tTWM2OD15Lki3NFY6KM7:TR?= MUHTRW5ITVJ?
KM-H2 NXvVfG9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;3TWM2OD15Lki4Olk1KM7:TR?= MkS2V2FPT0WU
RPMI-2650 MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;IXXRCUUN3ME23Mlk1PDF2IN88US=> NYnUO|JpW0GQR1XS
NCI-H226 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:4ZZRZUUN3ME24MlIyOTJ{IN88US=> MXzTRW5ITVJ?
MKN45 NFLzdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Lz[GlEPTB;OD6yOlYxOiEQvF2= NXWxXmdoW0GQR1XS
D-392MG MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLsTWM2OD16LkWyO|IzKM7:TR?= NX2ybmlyW0GQR1XS
RCC10RGB MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDTUoM6UUN3ME24Mlg3Pjl3IN88US=> Mlm2V2FPT0WU
CAL-51 M3TGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTQV3ZKSzVyPUmuNVAzPTFizszN NIXvfIJUSU6JRWK=
COLO-678 NFPybZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnTV3dFUUN3ME25MlMzQDFzIN88US=> MYnTRW5ITVJ?
SK-MEL-24 Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXlTWM2OD17LkW1PFU3KM7:TR?= MVrTRW5ITVJ?
SK-MEL-30 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLPNZZ4UUN3ME25Mlk1PDd4IN88US=> MmT5V2FPT0WU
MMAC-SF MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrmR5dKSzVyPUGwMlM6PjFizszN M17YSnNCVkeHUh?=
NTERA-S-cl-D1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTFyLk[1NFgh|ryP MYTTRW5ITVJ?
NB12 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFzLkWwN{DPxE1? M2fqTHNCVkeHUh?=
UACC-257 M3PY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFzLki2PVUh|ryP NFX2RYxUSU6JRWK=
LAN-6 NUTPUIpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFzLkm5Nlgh|ryP NH7Fe4dUSU6JRWK=
SW1573 NETHVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT2WVVWUUN3ME2xNk4{ODh4IN88US=> Ml7tV2FPT0WU
NMC-G1 NGrRZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rnOWlEPTB;MUKuOFE4PSEQvF2= NF;LXJNUSU6JRWK=
SHP-77 NWfaXGFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjuXFJ{UUN3ME2xNk42PTd2IN88US=> NELt[|JUSU6JRWK=
IGROV-1 NF7sUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED4cZpKSzVyPUGyMlY2PzNizszN NX3wS3FmW0GQR1XS
22RV1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETtdYJKSzVyPUGyMlgxPTlizszN MnzBV2FPT0WU
SK-MEL-3 NHjNSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK2W3FKUUN3ME2xN{4{QTd|IN88US=> Mkf3V2FPT0WU
NCI-H1563 M{HuPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\qTWM2OD1zMz60NlAzKM7:TR?= M3roWnNCVkeHUh?=
IGR-1 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T0Z2lEPTB;MUSuNFM1PyEQvF2= M1[4c3NCVkeHUh?=
EW-3 M1\MUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVziOmdzUUN3ME2xOE4yPjN7IN88US=> NUnsXXY1W0GQR1XS
JEG-3 NHy4botIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33EfGlEPTB;MUSuOFk2OyEQvF2= MnnVV2FPT0WU
ES3 MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\ZdIV3UUN3ME2xOE43PTZ{IN88US=> MXTTRW5ITVJ?
MDA-MB-175-VII MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTF2LkexNVEh|ryP NGqyNmxUSU6JRWK=
P30-OHK M4ixb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF3LkC0PVYh|ryP NH\U[4dUSU6JRWK=
GP5d NVjqW|JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH63b3RKSzVyPUG1MlE1PjZizszN M130cXNCVkeHUh?=
HMV-II NWf0PJBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF3LkOzN|Mh|ryP M{WzVXNCVkeHUh?=
COLO-679 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nye2lEPTB;MUWuOVAyKM7:TR?= NGC5c2dUSU6JRWK=
JAR NHKzSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\JTWM2OD1zNT63NlA2KM7:TR?= Ml[wV2FPT0WU
NCI-H1666 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfyTWM2OD1zNT65N|k6KM7:TR?= NVjtTpU3W0GQR1XS
SW48 NITNcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\yd|lKSzVyPUG1Mlk2OTZizszN NGjaZ5FUSU6JRWK=
NCI-H720 Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEW5W3hKSzVyPUG1Mlk6QDlizszN MnnCV2FPT0WU
HT-1197 NVPCbnQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL5bI1KSzVyPUG2MlA{PTJizszN NULkc45wW0GQR1XS
HL-60 M4jSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvMW3V{UUN3ME2xOk4xOzh2IN88US=> MVXTRW5ITVJ?
BEN M4XLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfkbGR1UUN3ME2xOk42PjN6IN88US=> NHv1SW5USU6JRWK=
HAL-01 M1X6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vVZ2lEPTB;MU[uPFkxQSEQvF2= M13FfXNCVkeHUh?=
SW900 NHTRXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF4LkmxN|Ih|ryP NXvlZXFLW0GQR1XS
SBC-1 NVTtNmV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe5SVZKSzVyPUG3MlU1OjlizszN M{XPeXNCVkeHUh?=
SH-4 NXrQOJVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELHXWdKSzVyPUG3MlU5PDFizszN M{LONXNCVkeHUh?=
UACC-62 NVHPN5g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e5dGlEPTB;MUeuO|Y{PyEQvF2= MmTrV2FPT0WU
BHT-101 NFK4elhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:1V3FKSzVyPUG5Mlg4ODVizszN MVzTRW5ITVJ?
DB M3flemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\q[G13UUN3ME2yNU42PjR7IN88US=> MWXTRW5ITVJ?
SK-MEL-1 NIrxSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPYOm1KSzVyPUKxMlU5PzJizszN MnPmV2FPT0WU
NCI-H747 MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzPfFZKSzVyPUKyMlc{PzlizszN M2LXUHNCVkeHUh?=
SK-LU-1 MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTJ|LkO1NlQh|ryP MnHyV2FPT0WU
KG-1 NYH2cpNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rRVmlEPTB;MkOuOFk1PiEQvF2= NF7nWXdUSU6JRWK=
LXF-289 MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTBTWM2OD1{Mz63NVQh|ryP M2joWnNCVkeHUh?=
HCC1954 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\1WmlEPTB;MkSuPFg1PCEQvF2= MYjTRW5ITVJ?
Ramos-2G6-4C10 NXvRcmhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T5d2lEPTB;Mk[uOFk5OSEQvF2= MVPTRW5ITVJ?
DBTRG-05MG NXvQ[5RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorkTWM2OD1{Nj62OFg5KM7:TR?= MYjTRW5ITVJ?
NCI-H2052 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Tyb2lEPTB;MkeuOVY5PCEQvF2= MULTRW5ITVJ?
RMG-I Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDlWmdKSzVyPUK5MlQyOzlizszN M2fab3NCVkeHUh?=
H9 NYjLc412T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNzLkOwNFgh|ryP MkDYV2FPT0WU
GR-ST MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTN{LkS0OVMh|ryP M1jpenNCVkeHUh?=
Mo-T M4P6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;5NWdKSzVyPUOyMlUxPDZizszN MYLTRW5ITVJ?
SW1088 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrITIVKSzVyPUOyMlk5ODFizszN NVrqTXB1W0GQR1XS
LB2518-MEL NX\FeIJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILRbY9KSzVyPUOzMlA4QTdizszN Ml3CV2FPT0WU
NCI-H82 NHWzbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTN|LkG2OlEh|ryP NHfOfWFUSU6JRWK=
LAMA-84 M2DPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTGTWM2OD1|ND62NFc{KM7:TR?= MkDEV2FPT0WU
KYSE-450 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jhSWlEPTB;M{SuOlc4PiEQvF2= MWTTRW5ITVJ?
LU-99A MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\IVo9KSzVyPUO1MlAxODdizszN M3HGTnNCVkeHUh?=
BE-13 NVTUPHluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nQNmlEPTB;M{WuOlU1PSEQvF2= NFfoUHZUSU6JRWK=
GAK NH36RmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTObo1OUUN3ME2zOU43QTVizszN NXfZNVM{W0GQR1XS
NCI-H1573 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vBcWlEPTB;M{WuPFgyQCEQvF2= NXXCb3BoW0GQR1XS
AsPC-1 M{jSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3q[WhKSzVyPUO2MlE2OjdizszN MVvTRW5ITVJ?
HDLM-2 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTN4LkOxOkDPxE1? MofOV2FPT0WU
NCI-H441 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTN5LkC2PVEh|ryP MnPPV2FPT0WU
CAL-27 NGTSOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDO[oVKSzVyPUO3MlczOzFizszN NIW3V2dUSU6JRWK=
OVCAR-3 M1\leWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[2UVFCUUN3ME2zPU4{OThzIN88US=> NVzhXGl4W0GQR1XS
RPMI-8226 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme5TWM2OD1|OT61PVgh|ryP MXXTRW5ITVJ?
EFO-21 NYrsdJFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTRyLkW4NVQh|ryP Mk[5V2FPT0WU
SNU-C2B MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTRzLkWwPFQh|ryP M4KyT3NCVkeHUh?=
VM-CUB-1 NIfOeIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTR|LkiwN|ch|ryP NHLDNmhUSU6JRWK=
NCI-H2087 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjHUY5KSzVyPUS1MlAzOzNizszN M3:xZ3NCVkeHUh?=
EW-16 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P6O2lEPTB;NE[uN|E{PyEQvF2= MlSzV2FPT0WU
SK-N-AS MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfnTWM2OD12Nj63NVY4KM7:TR?= NXTVT485W0GQR1XS
COR-L105 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rkTGlEPTB;NE[uPFg2PyEQvF2= MonZV2FPT0WU
DEL NVv5c4d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y4RmlEPTB;NEiuNFQzQSEQvF2= NIjsbWZUSU6JRWK=
JVM-2 NF6yblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPUOnNKSzVyPUS4MlA2PThizszN MmnaV2FPT0WU
KARPAS-45 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LkOGlEPTB;NEmuOFU{QCEQvF2= NUfHTY1tW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+55% PEG 300+ddH2O
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Related Antibodies

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID